Free Trial
NASDAQ:IMUX

Immunic (IMUX) Stock Price, News & Analysis

Immunic logo
$0.69 -0.01 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 +0.01 (+1.83%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunic Stock (NASDAQ:IMUX)

Key Stats

Today's Range
$0.69
$0.74
50-Day Range
$0.66
$1.28
52-Week Range
$0.56
$2.11
Volume
962,473 shs
Average Volume
965,801 shs
Market Capitalization
$66.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.60
Consensus Rating
Buy

Company Overview

Immunic Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

IMUX MarketRank™: 

Immunic scored higher than 52% of companies evaluated by MarketBeat, and ranked 570th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunic has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunic has only been the subject of 4 research reports in the past 90 days.

  • Read more about Immunic's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunic are expected to grow in the coming year, from ($0.94) to ($0.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunic is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunic is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunic has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunic's valuation and earnings.
  • Percentage of Shares Shorted

    8.14% of the float of Immunic has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunic has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Immunic has recently increased by 75.06%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immunic does not currently pay a dividend.

  • Dividend Growth

    Immunic does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.14% of the float of Immunic has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunic has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Immunic has recently increased by 75.06%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Immunic has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Immunic this week, compared to 4 articles on an average week.
  • Search Interest

    38 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 280% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,150.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Immunic is held by insiders.

  • Percentage Held by Institutions

    51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunic's insider trading history.
Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

IMUX Stock News Headlines

Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

IMUX Stock Analysis - Frequently Asked Questions

Immunic's stock was trading at $1.00 on January 1st, 2025. Since then, IMUX stock has decreased by 31.0% and is now trading at $0.6904.
View the best growth stocks for 2025 here
.

Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25).

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX).

Company Calendar

Last Earnings
5/15/2025
Today
7/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMUX
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.60
High Stock Price Target
$28.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,557.1%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$100.51 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
3.50

Miscellaneous

Free Float
91,410,000
Market Cap
$67.07 million
Optionable
Optionable
Beta
1.49
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:IMUX) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners